What is Pathfinder Cell Therapy, Inc. (PFND) stock price today?

Pathfinder Cell Therapy, Inc. (PFND) is currently trading at $0.00.

What is PFND P/E ratio?

Pathfinder Cell Therapy, Inc.'s P/E ratio is -0.04. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is PFND return on equity (ROE)?

Pathfinder Cell Therapy, Inc.'s return on equity (ROE) is 33.33%. ROE measures net income relative to shareholders' equity. Shareholders' equity is negative, so ROE is not a meaningful measure for this company.

What is Pathfinder Cell Therapy, Inc.'s market cap?

Pathfinder Cell Therapy, Inc. has a market capitalization of $66716.

OTC · Biotechnology

Pathfinder Cell Therapy, Inc. (PFND) Stock

$0.00 OTC: PFND Healthcare

Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine.

Valuation

Metric	Value
Price	$0.00
Market Cap	$66716
P/E Ratio	-0.04
P/B Ratio	-0.01
P/S Ratio	0.00
EPS (TTM)	$0.00
52-Week High	$0.00
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	33.33%
ROA	—
ROCE	18.83%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.83
Current Ratio	0.01

Annual Financials (USD)

Metric	2010	2011	2012	2013	2014
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-2.0M	$4.0M	$-2.0M	$-2.0M	$-1.0M
Net Profit	$-2.0M	$-19.0M	$-2.0M	$-2.0M	$-2.0M
EPS	$0.00	$-0.04	$0.00	$0.00	$0.00
Op Margin	-726.5%	5378.1%	-1807.0%	-2961.1%	—

Balance Sheet (USD)

Metric	2010	2011	2012	2013	2014
Total Assets	$0	$1.0M	$0	$0	$0
Total Liabilities	$1.0M	$1.0M	$3.0M	$5.0M	$6.0M
Cash	$0	$0	$0	$0	$0
Borrowings	$0	$0	$2.0M	$4.0M	$5.0M

Cash Flow (USD)

Metric	2010	2011	2012	2013	2014
Operating Cash Flow	$-1.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M
Investing Cash Flow	$0	$-1.0M	$0	$0	$0
Financing Cash Flow	$0	$0	$0	$2.0M	$1.0M
Net Cash Flow	$-1.0M	$0	$0	$0	$0
Free Cash Flow	$-1.0M	$-2.0M	$-2.0M	$-2.0M	$-1.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-4.50
FCF Yield	-1443.43%
Quick Ratio	0.01
Interest Coverage	—
Return 1Y	0.00%
Return 3Y	0.00%
Return 5Y	—

Ownership

Insiders Held0.00%

Institutions Held0.00%

Institutions Float Held0.00%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BITRFBiotron Limited	$0.04	+0.00%	-6.67	$37.63M	0.00%
BNGIBangi Inc.	$0.00	—	0.00	$5254	0.00%
BPTSYBiophytis S.A.	$0.25	+0.00%	-0.02	$105224	0.00%
CBDGTHC Farmaceuticals, Inc.	$0.03	+0.00%	46.50	$505872	0.00%
IPIXInnovation Pharmaceuticals Inc.	$0.00	—	-0.32	$1.04M	0.00%

About Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy, Inc. is an emerging biotechnology firm specializing in regenerative medicine. This company is dedicated to pioneering innovative cell-based and associated treatments designed to address a range of illnesses and health issues, particularly those involving localized cellular injury within organs. Its proprietary technology shows promise for tackling conditions such as diabetes, kidney disease, heart attacks (myocardial infarction), and peripheral vascular ailments, among others. Established in 2008, the company maintains its corporate headquarters in Cambridge, Massachusetts.

Pathfinder Cell Therapy, Inc. (PFND) stock trades at $0.00 with a market capitalization of $66716. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.04, reflecting a net loss over the last twelve months, a negative price-to-book of -0.01, reflecting negative shareholders' equity, price-to-sales of 0.00.

On profitability, Pathfinder Cell Therapy, Inc. generates a return on equity (ROE) of 33.33% (not meaningful, as shareholders' equity is negative), return on capital employed of 18.83%.

Official website: www.pathfindercelltherapy.com